ArticleJournal of computer-aided molecular design2026
NetPolicy-RL: network-informed offline reinforcement learning for pharmacogenomic drug prioritization.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-scale pharmacogenomic screens provide extensive measurements of drug response across diverse cancer cell lines; however, most computational approaches emphasize point-wise sensitivity prediction or static ranking, which are poorly aligned with practical decision-making, where only a limited number of candidate drugs can be tested. We propose NetPolicy-RL, a biologically informed and decision-centric framework for pharmacogenomic drug prioritization that integrates network diffusion modeling with offline reinforcement learning. Drug selection for each cell line is formulated as an offline contextual bandit problem, enabling implicit optimization of ranking quality through a decision-oriented reward formulation rather than surrogate regression objectives. Mechanistic biological context is incorporated by propagating drug targets over curated interaction networks (STRING and Reactome) using random walk with restart, and combining the resulting diffusion profiles with cell-specific molecular importance derived from multi-omics data to compute network disruption scores. These biologically grounded signals are integrated with normalized drug response measurements to construct a joint state representation, which is optimized using an offline actor-critic architecture. Across held-out test splits, NetPolicy-RL consistently outperforms global ranking heuristics and learning-to-rank baselines, achieving statistically significant improvements in per-cell Normalized Discounted Cumulative Gain (NDCG@10) and substantial reductions in per-cell regret. Relative to GlobalTopK, the policy improves NDCG@10 for 88.7% of cell lines, while improvements exceed 95% compared with LambdaMART and regression-to-ranking baselines. Ablation analyses indicate that neither empirical response signals nor network-derived features alone are sufficient within the evaluated setting and that their integration yields the most robust performance. Overall, this study demonstrates that combining mechanistic network biology with offline policy learning provides an effective and interpretable framework for drug prioritization in precision oncology.
Indexed as
Identifiers
42249216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.